Glenmark gets FDA nod for calcipotriene ointment
This article was originally published in Scrip
Glenmark Generics, a US subsidiary of India's Glenmark, has received final approval from the US FDA for calcipotriene ointment 0.005%, a generic version of Leo Pharmaceuticals' plaque psoriasis treatment, Dovonex. Leo Pharmaceuticals marketed Dovonex ointment from December 1993 until April 2007, when the product was discontinued due to lack of commercial viability, Glenmark said. Leo still markets a line of Dovonex products including a cream and a topical solution. Dovonex reported peak sales of about $93 million in 2006.
You may also be interested in...
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.